Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality globally. According to the 2019 American College of Cardiology/American Heart Association Guideline on the Primary Prevention of Cardiovascular Disease, which of the following therapies should be considered first for adults with type 2 diabetes mellitus for whom medication is indicated to reduce ASCVD risk?
Better luck next time
Adults with T2DM and additional ASCVD risk factors who require glucose-lowering therapy despite initial lifestyle modifications and metformin, may initiate an SGLT-2 inhibitor or a GLP-1R agonist to improve glycemic control and reduce CVD risk.
For more cardiovascular disease content, visit the Resource Center.
Nice job!